scholarly journals PBPK Modeling to Predict Drug‐Drug Interactions of Ivosidenib as a Perpetrator in Cancer Patients and Qualification of the Simcyp Platform for CYP3A4 Induction

2021 ◽  
Author(s):  
Jayaprakasam Bolleddula ◽  
Alice Ke ◽  
Hua Yang ◽  
Chandra Prakash
Keyword(s):  
Drug Interactions ◽  
Cancer Patients ◽  
Pbpk Modeling ◽  
Cyp3a4 Induction

The burden of polypharmacy and drug–drug interactions in older cancer patients treated with immunotherapy

2021 ◽  
pp. 107815522110120
Author(s):  
Deniz C Guven ◽  
Gozde Kavgaci ◽  
Oktay H Aktepe ◽  
Hasan C Yildirim ◽  
Taha K Sahin ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Cancer Patients ◽  
Injury Risk ◽  
Checkpoint Inhibitors ◽  
High Rate ◽  
Potentially Inappropriate Medications ◽  
Inappropriate Prescription ◽  
Prescription Practices ◽  
Increased Risk ◽  
Older Cancer Patients

Introduction Polypharmacy is a common problem in older cancer patients, although the data about polypharmacy and potentially inappropriate prescription practices is limited in patients treated with immune checkpoint inhibitors (ICIs). Therefore, we aimed to evaluate the polypharmacy frequency and drug-drug interactions in older cancer patients (≥65 years) treated with ICIs. Methods A total of 70 geriatric patients with advanced cancer were included. The polypharmacy was defined as regular use of 5 or more drugs. The START/STOPP Criteria Version 2 was used for the potentially inappropriate medications (PIM) and potential prescription omissions (PPO). The Medscape Drug Interaction Checker was used for potential drug-drug interactions. Results The patients had a median of 6 regular drugs, and polypharmacy was present in 77.1%. The polypharmacy risk was significantly increased in patients over 75 years of age (p = 0.028) and with opioid use (p = 0.048). The 50% of patients had category D or X interactions. Patients with higher Charlson Comorbidity Index had significantly increased risk for drug interactions (CCI ≤10 vs. >10, p = 0.017). The PIMs were present in 44.3% and the PPOs in 68.6% of the patients. While the overall survival and immune related adverse events were similar according to polypharmacy, in patients using seven or more drugs, the acute kidney injury risk was increased (HR: 4.667, p = 0.038). Conclusion In this study, we observed a high rate of polypharmacy and inappropriate prescription practices in ICI-treated patients. These issues pointed out the need for improved general medical care and attention for better comedication management in ICI-treated patients.

scholarly journals Potential Drug Interactions in Cancer Patients Receiving Supportive Care Exclusively

2008 ◽  
Vol 35 (5) ◽  
pp. 535-543 ◽  
Author(s):  
Rachel P. Riechelmann ◽  
Camilla Zimmermann ◽  
Sheray N. Chin ◽  
Lisa Wang ◽  
Aoife O'Carroll ◽  
...  
Keyword(s):  
Supportive Care ◽  
Drug Interactions ◽  
Cancer Patients ◽  
Potential Drug

Prevalence of potential drug-drug interactions in breast cancer patients and determination of their risk factors

2020 ◽  
pp. 107815522096321
Author(s):  
Rashida Bibi ◽  
Saira Azhar ◽  
Ayesha Iqbal ◽  
Hajera Jabeen ◽  
Umm-e Kalsoom ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Drug Interactions ◽  
Cancer Patients ◽  
Health Care Professionals ◽  
Potential Drug ◽  
Breast Cancer Patients ◽  
Medication Regimen ◽  
Cancer Data ◽  
Chemotherapy Drugs

Breast cancer patients use numerous medications, which include cytotoxic chemotherapy drugs, hormonal agents and supportive medication, so they are more vulnerable to potential adverse drug interactions. This study aimed to evaluate frequency, severity, clinical importance and risk factors responsible for the Drug-drug interactions (DDIs) in a cohort of patients suffering from breast cancer. Data was obtained from 150 patients in the oncology ward (both inpatient and outpatient) with a confirmed diagnosis of breast cancer and currently receiving standard breast cancer-directed treatment. The data was recorded into a pre-designed form specifically made for this study through individual patient interviews and by reviewing the detailed medical chart records of the patients. DDIs were identified by using drug interaction software such as Medscape mobile application and Micromedex version 2. The results of this study showed that all patients were female. The mean numbers of drugs that patients used were 7. Potential drug interactions were identified in 92% of the patients. When drug groups were overviewed, 32% of interactions were between anti neoplastic drugs, 62.9% interactions were between the anti neoplastic agent and supportive care drugs and 5% of them were between anti-cancer drugs and drugs used to treat comorbidities. Major DDIs were found in 62.2% of patients, 25.3% of DDIs were moderate and 12.4% were minor. The number of drugs, comorbid diseases, and selection of chemo protocols were the risk factors for drug interactions. Most of the DDIs found in breast cancer therapy may have adverse consequences on patient health and therapeutic outcomes. Therefore, health care professionals should review the medication regimen of patients with breast cancer before starting any chemotherapy treatment.

scholarly journals Corrigendum to “Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors” [Cancer Treatm. Rev. 74 (2019) 21–28]

2019 ◽  
Vol 81 ◽  
pp. 101913
Author(s):  
Stefano Fogli ◽  
Marzia Del Re ◽  
Giuseppe Curigliano ◽  
Ron H. van Schaik ◽  
Patrizio Lancellotti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Interactions ◽  
Cancer Patients ◽  
Breast Cancer Patients

scholarly journals Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors

2019 ◽  
Vol 74 ◽  
pp. 21-28 ◽  
Author(s):  
Stefano Fogli ◽  
Marzia Del Re ◽  
Giuseppe Curigliano ◽  
Ron H. van Schaik ◽  
Patrizio Lancellotti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Interactions ◽  
Cancer Patients ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document